+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06102395

Phase III Study of Pembrolizumab With Standard Chemotherapy Before Surgery in Advanced Head and Neck Squamous Cell Carcinoma

Led by Beijing Tongren Hospital · Updated on 2023-10-30

272

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of pembrolizumab combined with standard chemotherapy as a neoadjuvant treatment for patients with untreated stage IIIA to IVB head and neck squamous cell carcinoma. This includes cancers of the oral cavity, oropharynx, hypopharynx, and larynx. The study is a phase III, prospective, open-label, multi-center trial aiming to improve the rate of complete pathological response before surgery or radiotherapy. Participants are randomly assigned to receive either pembrolizumab plus chemotherapy or chemotherapy alone for two cycles. The chemotherapy regimen includes drugs such as cisplatin, carboplatin, nedaplatin, nab-paclitaxel, docetaxel, liposomal paclitaxel, or fluorouracil. After neoadjuvant treatment, imaging assessments determine further treatment complete responders receive radiotherapy with or without chemotherapy, while partial responders or those with stable disease proceed to surgery followed by standard care. Disease progression leads to standard treatment. Adverse reactions are closely monitored throughout. Participants undergo regular follow-ups every three months for the first year and every six months for the following three years. These visits include assessments of treatment response, adverse events, quality of life, and survival outcomes. Researchers measure the pathological complete response rate at 12 weeks as the primary outcome, alongside secondary outcomes such as response rates, event-free survival, overall survival, functional preservation, and treatment-related adverse events. The total study duration may extend up to several years to capture long-term results.

CONDITIONS

Brief Title

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Research Team

Z

Zhigang Huang

Y

Yang Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here